Alenbe 70mg Hasan treatment for osteoporosis (2 blisters x 2 tablets)

Dosage form Box of 2 blisters x 2 tablets
Specifications Alendronic Acid
Ingredient Osteoporosis, osteoporosis in South, Paget bone

Ingredient

Composition information	Content
Alendronic Acid	70mg

Uses

indications

Alenbe 70 mg is indicated in the following cases:

Treatment of osteoporosis in postmenopausal women.

Pharmacology

Alendronat is an aminobisphosphonate that inhibits bone elimination without directly affecting the bone formation process.

Pre -clinical studies show that alendronat accumulates selectively at the active bone pepper position, inhibit the activity of the cell cancel.

Clinical studies show that Alendronat treatment can significantly increase the volume of bone in the spine, femur and transfer.

In clinical studies in menopausal women from 40 to 85 years old with osteoporosis (determined to have low bone mass, at least two standard lower levels of the average before menopause), Alendronat treatment significantly reduces the number of spine fractures after 3 years of medication. The density of bone minerals increases clearly after 3 months of Alendronat treatment and continues to increase during the drug.

Dynamic pharmacokinetics

compared to an intravenous dose, oral bioavailability in women is 0.7% with a dose of 5 - 70 mg, oral after 1 fast -up and 2 hours before a standard breakfast. Born is reduced to 0.46% and 0.39% when taking Alendronat 1 hour as well as 30 minutes before the standard breakfast.

In the study of osteoporosis, Alendronat works well when drinking at least 30 minutes before the first meal of the day. Birth is negligible when drinking Alendronat with or after breakfast 2 hours. Cafe and orange juice reduces the bioavailability of alendronat by about 60%.

Prelise clinical studies show that after an intravenous injection of 1 mg/kg, an alendronat transient distribution in soft tissues but then re -distributed into the bone or excreted through the urine. Links to protein in human plasma is approximately 78%.

There is no evidence that alendronat is metabolized in animals and people.

After the Alendronat intravenous injection marks C14, about 50% are found in urine for 72 hours and very few or not seen in the feces. After intravenous injection of a single dose of 10 mg, the kidney clearance of the alendronate is 71 ml/min and the body clearance does not exceed 200 ml/min. Plasma concentration decreased by more than 95% within 6 hours after intravenous injection. In humans, the sale time of the drug is estimated to be over 10 years, the light of the release of Alendronat from the skeleton.

Pre -clinical studies show that the amount of alendronat does not accumulate in the bone is rapidly eliminated through the urine. Although there is no clinical data, the elimination of alendronate through the kidneys may decrease in people with kidney failure like animals. Therefore, the amount of alendronat accumulated in the bone may be higher in the kidney failure.

Before taking Alenbe 70mg Hasan treatment for osteoporosis (2 blisters x 2 tablets)

How to use

has not clearly defined the optimal time for osteoporosis treatment with bisphosphonate. The need to continue treatment should be assessed regularly based on the benefits and risks of 70 mg for each patient, especially when the treatment time lasts more than 5 years.

Used orally. To absorb well, take medicine with a amount of water about 180 - 240 ml (do not use mineral water, including fruit juice, coffee) at least 30 minutes before meals, the first drink of the day or before taking other drugs.

No sucking or chewing tablets.

Avoid lying in at least 30 minutes after taking allele 70 to make the stomach easily and reduce the potential of esophageal irritation.

Do not take medicine at bedtime or before waking up during the day.

Dosage

Take 1 capsule/time/week. (equivalent to 70 mg of alendronic acid/week/week).

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose?

There is no separate information about the treatment of Alendronat overdose. Milk and antacidants should be used to link alendronat. Due to the risk of esophageal irritation, do not cause vomiting and the patient still has to sit upright. The separation is not effective.

What to do when you forget 1 dose? If it is nearly time to take the next dose, skip the forgotten dose and take medicine at the next recommended dose. Do not take double dose to compensate for the forgotten dose.

Side Effects

When using 70 mg alenbe, you may experience unwanted effects (ADR).

Side effects because the use of 70 mg alenbe is usually mild and generally does not need to stop the drug, mainly unwanted effects in the digestive tract.

Common, ADR> 1/100

Headache, flatulence, acid reflux, esophageal ulcer, difficulty swallowing, bloating.

Uncommon, 1/1000

ban, erythema, gastritis.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Alenbe 70 mg contraindicated in the following cases:

Esophageal deformities slow the removal of narrow esophagus or non -relaxing esophagus.

Inability to stand or sit upright for at least 30 minutes.

Hypersensitivity to bisphosphonate or any ingredient of the drug.

Reducing blood calcium.

Be cautious when using

There have been reports on events in esophagus, esophagitis, esophagitis, esophagus, sometimes accompanied by bleeding in patients being treated with Alendronat.

Stop using Alendronat and see a doctor if it is difficult to swallow, swallow pain or sternum pain. The risk of serious esophageal events is more common in patients right after taking alendronat and/or not taking pills with enough water (180 - 240 ml) and/or continuing to take Alendronat after seeing symptoms of esophageal irritation.

Alendronate can irritate the above gastrointestinal mucosa. Due to the more severe ability to make the disease, be careful when using alendronat in patients with the gastrointestinal pathology (difficulty swallowing, real pants, gastritis, duodenum or ulcer).

Must treat blood calcium loss before starting with Alendronat treatment. Effective treatment of other disorders of inorganic metabolism (vitamin D deficiency).

Additional calcium and vitamin D if the daily amount in the diet is not enough.

The ability to drive and operate machinery

does not affect the ability to drive and operate machinery.

Pregnancy

Through the effect on lip balca balance and bone metabolism, alendronate can cause harm to the fetus or for newborn babies. It has been found to be difficult and creating not complete bones in animal studies. It does not exclude that may also be related to humans, so it is not allowed to use 70 mg alenbe during pregnancy.

The period of breastfeeding

whether the alendronat is excreted in the breast milk or not, need to be cautious when taking the drug for women who are in breast -feeding period.

Drug interaction

estrogen: Safe and effective of simultaneous use of hormone replacement therapy and alendronat for postmenopausal women have not been determined, so it is not recommended this simultaneous usage.

Calcium supplements and antacids: can reduce the absorption of alendronat. So patients have to wait at least half an hour after taking Alendronat to use any other drug.

Acetylsalicylic acid: In clinical studies, the proportion of unwanted reactions in the gastrointestinal tract on patients with simultaneous use of alendronat dose is greater than 10 mg/day with acetylsalicyl compounds.

Non -steroid anti -inflammatory drugs (NSAID): Alendronat can be used in patients who are taking NSAID drugs. However, NSAID drugs often cause gastrointestinal irritation, so they must be cautious when used with Alendronat.

Storage

Cool dry place, under 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.